Literature DB >> 19807450

Global cost modeling analysis of HIV-1 and HCV viral load assays.

Tarek Elbeik1, Yi-Ming Arthur Chen, Serguei V Soutchkov, Richard A Loftus, Scott Beringer.   

Abstract

This review addresses hidden costs associated with the Bayer VERSANT assay, Roche AMPLICOR MONITOR test and COBAS AMPLICOR MONITOR test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effective approach for these tests is presented. The analyses demonstrate the need for manufacturers to consider labor and supply costs when marketing a kit in resource-poor countries, noting that marketing strategies need to change. In the absence of any proven monitoring alternative, emphasis is placed on increasing market share to promote significant reduction in kit prices to suit the demands of markets in resource-poor countries. Finally, recommendations are made to improve the overall cost structure of viral load testing. This review is intended as a tool to optimize assay usage in attaining the lowest performance costs by assay and is not to endorse any test, as will become apparent.

Entities:  

Year:  2003        PMID: 19807450     DOI: 10.1586/14737167.3.4.383

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  7 in total

1.  Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow.

Authors:  Tarek Elbeik; Norman Markowitz; Patricia Nassos; Uday Kumar; Scott Beringer; Barbara Haller; Valerie Ng
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

2.  Instrument-free nucleic acid amplification assays for global health settings.

Authors:  Paul LaBarre; David Boyle; Kenneth Hawkins; Bernhard Weigl
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2011-05-16

3.  Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA).

Authors:  Tarek Elbeik; Johan Surtihadi; Mark Destree; Jed Gorlin; Mark Holodniy; Saeed A Jortani; Ken Kuramoto; Valerie Ng; Roland Valdes; Alexandra Valsamakis; Norah A Terrault
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

4.  Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting.

Authors:  Jay Gerlach; Magda Sequeira; Vivian Alvarado; Christian Cerpas; Angel Balmaseda; Alcides Gonzalez; Tala de Los Santos; Carol E Levin; Juan Jose Amador; Gonzalo J Domingo
Journal:  J Int AIDS Soc       Date:  2010-11-05       Impact factor: 5.396

Review 5.  Current practices in laboratory monitoring of HIV infection.

Authors:  Madhu Vajpayee; Teena Mohan
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

Review 6.  HIV-1 viral load assays for resource-limited settings.

Authors:  Susan A Fiscus; Ben Cheng; Suzanne M Crowe; Lisa Demeter; Cheryl Jennings; Veronica Miller; Richard Respess; Wendy Stevens
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

7.  Introduction of an automated system for the diagnosis and quantification of hepatitis B and hepatitis C viruses.

Authors:  Mt Cabezas-Fernandez; Mi Cabeza-Barrera
Journal:  Open Virol J       Date:  2012-11-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.